Biologics help reduce inflammation in HS. Biologics for HS include Humira and Cosentyx. Humira is an injectable medication approved by the United States Food and Drug Administration (FDA ...

predicted response to adalimumab (Humira) treatment for patients with hidradenitis suppurativa, post hoc analysis of the PIONEER I and II trials found. At 12 weeks of follow-up, adults with ...

Hidradenitis suppurativa is managed with biologics like adalimumab and secukinumab, approved for moderate-to-severe cases. Adalimumab, a TNF-α inhibitor, was FDA-approved in 2015, while ...

use of adalimumab in those who require biologics, and limiting the use of doxycycline among those who are breastfeeding. Other categories of patients with HS include the following recommendations ...

If you are using this medication to treat psoriasis, hidradenitis suppurativa ... this to prevent a serious TB infection while using adalimumab. To lower the chance of getting cut, bruised ...

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

hidradenitis suppurativa, and juvenile idiopathic arthritis. Humira is patent protected in the US until 2023, where the majority of its sales are based. Vertex's gene-editing therapy for sickle ...

Indications for which Humira’s regulatory exclusivity have already lapsed include rheumatoid arthritis, Crohn’s disease, plaque psoriasis, ulcerative colitis, and hidradenitis suppurativa.

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...